摘要
目的:探讨应用吡柔比星(THP)进行膀胱内灌注预防膀胱癌术后复发的疗效和安全性.方法:对68例初发的浅表性膀胱癌术后患者定期进行THP膀胱内灌注治疗,随访18~48个月.结果:全组无肿瘤复发率为85.3%,复发率为14.7%,29例于膀胱灌注期间出现膀胱刺激症状,其中4例因为不能耐受,暂停灌注,其余患者均完成治疗.所有患者未见明显的全身性药物反应.结论:THP膀胱内灌注预防膀胱癌术后复发的疗效满意,病人耐受性好,无全身性给药的毒副反应.
Objective :To investigate the effect of intravesical instillation of pirarubicin or mitomycin in the prophylaxis of local recurrence after resection of bladder cancer. Methods :68 patients with bladder cancer after TURBT or partial cystectomy received intravesical instillation of pirarubicin. All these patients were followed up for 18 to 48 months. Results:Recurrence rate in the patients treated with pirarubicin was 14. 7%. No systemic side effect has been observed in all patients. Conclusion:Intravesical instillation of pirarubicin has been effective against local recurrence of bladder cancer without systemic side effects.
出处
《临床肿瘤学杂志》
CAS
2005年第2期157-158,160,共3页
Chinese Clinical Oncology
关键词
膀胱肿瘤
吡柔比星
膀胱灌注
Bladder neoplasms
Pirarubicin
Intravesical instillation